Dual GLP-1/GIP drugs reduce liver fat 2x more than GLP-1-only drugs in MAFLD meta-analysis | Research

The takeaway

Meta-analysis of 26 RCTs (3,453 patients) shows dual GLP-1/GIP agonists reduce liver fat 2x more than GLP-1 mono-agonists (-7.15% vs -3.37%), with treatment >48 weeks needed for optimal outcomes and GRADE-evaluated evidence.

Dual agonists: 2x liver fat reduction
Dual GLP-1/GIP drugs reduced liver fat -7.15% vs -3.37% for GLP-1 alone in MAFLD—supporting tirzepatide as the preferred option for fatty liver

What the researchers found

GLP-1RA liver fat: -3.37% (p significant). Dual GLP-1/GIP: -7.15% (p significant). Dual > mono for liver fat (p significant). ↓ALT, AST, glycemic markers. >48 weeks needed for optimal results. 26 RCTs, 3,453 patients. GRADE evaluated.

Why it matters

MAFLD affects 30% of the global population with few effective treatments. Showing dual GLP-1/GIP drugs are 2x more effective than GLP-1 alone for liver fat helps clinicians choose the optimal agent.

How the study worked

Systematic review and meta-analysis. PubMed, Cochrane, Web of Science, Scopus through July 2025. 26 RCTs. Subgroup analyses by receptor target, duration, control, age. GRADE framework.

What this study cannot tell us

Heterogeneous trial designs. Different GLP-1 and dual agents pooled. MAFLD definitions varied. Long-term histological outcomes limited.

How to read the evidence

Meta-analysis of 26 RCTs with GRADE evaluation. Moderate to high quality evidence.

When this study was published

Published in 2025; literature through July 2025.

The bigger picture

Dual GLP-1/GIP agonists (like tirzepatide) emerge as the most effective liver-targeted metabolic drugs, supporting their use in the increasingly common overlap of obesity, diabetes, and fatty liver.

Questions still open

Does the superior liver fat reduction with dual agonists translate to less fibrosis?
Should tirzepatide be first-line for MAFLD with diabetes?
What minimum treatment duration is clinically meaningful?

Common questions

Which drug works best for fatty liver?

In this meta-analysis, dual GLP-1/GIP drugs (like tirzepatide) reduced liver fat by about 7%—twice as much as GLP-1 drugs alone (about 3.4%). Both classes also improved liver enzymes and blood sugar. Treatment should continue for at least 48 weeks for optimal results.

Can GLP-1 drugs treat fatty liver disease?

Yes—both GLP-1 drugs and dual GLP-1/GIP drugs significantly reduce liver fat and improve liver enzymes. This meta-analysis of 26 clinical trials confirms their effectiveness, with dual agonists (like tirzepatide) showing the greatest liver benefit. They work best in patients who also have diabetes or obesity.

Read the original research

Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials.

BMC gastroenterology, 25(1), 765

View on PubMed ↗Publisher’s paper ↗

Citation

Tamilwanan, Surtika; Aziz, Zoriah; Rong, Lim Yan; Bitar, Ahmad Naoras; Zarzour, Raghdaa Hamdan Al; Alshehade, Salah A. (2025). Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials.. BMC gastroenterology, 25(1), 765. https://doi.org/10.1186/s12876-025-04358-0